Curative, platinum-based cytoxic drug therapy in a renal transplant recipient with metastatic testicular cancer.
Since June 1979, the authors have had the opportunity to treat a renal homograph recipient who developed primary embryonal cell testicular carcinoma with retroperitoneal and pulmonary metastases. This patient was treated with an induction chemotherapy protocol of vinblastine sulfate, bleomycin, and cisplatin and has remained free of disease through June 1985, without loss of his renal homograph. Cisplatin-based cytoxic drug therapy can be delivered safely to a renal transplant recipient without causing kidney damage, and, in this case, achieved a cure of metastatic testicular cancer.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D012186:Retroperitoneal Neoplasms / Q000556:secondary; D013724:Teratoma / Q000188:drug therapy* / Q000473:pathology; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014747:Vinblastine / Q000008:administration & dosage
D007166:Immunosuppressive Agents; D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin